Israel genome firm Evogene enters medical cannabis field seeking better products

422

Evogene Ltd. , a plant genomics firm whose shares are traded on the Nasdaq and on the Tel Aviv Stock Exchange, said Wednesday it has set up a subsidiary that will focus on developing medical cannabis products made from better and higher quality leaf yields. In a statement, Evogene said it has been evaluating the medical cannabis field for more than a year and has obtained governmental approval for its research program and the establishment of a research facility.

Ga naar Bron